AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbCellera Biologics reports robust earnings and growth opportunities ahead

AbCellera Biologics demonstrated strong financials and growth in Q4 2022, with a focus on building an engine for antibody discovery and development.
The company's strategic approach to partnerships and contract negotiations provides flexibility and potential for increased value creation.
Despite challenges in decision-making and program advancement, AbCellera's business model and liquidity position position it well for future opportunities.

AbCellera Biologics (ABCL) reports solid Q1 performance and eyes strategic growth opportunities

AbCellera Biologics (ABCL) showcases a strong performance in Q1 2023, focusing on long-term value creation and strategic partnerships.
Despite challenges in revenue streams and resource allocation, the company's emphasis on technology development and program diversity bodes well for future growth.
Opportunities lie in expanding partnerships, leveraging advancements in cancer therapy, and driving innovation in drug development for sustained success.

AbCellera reports Q2 revenue growth, faces clinical development uncertainty

AbCellera Biologics reported mixed financial results for Q2 2023, with revenue growth but a net loss due to continued investments.
The company showcased strengths in patent defense, R&D capabilities, and partnerships, while facing challenges in clinical development uncertainty and financial performance.
Opportunities lie in global therapeutics discovery, liquidity strength, and collaboration with Eli Lilly for COVID-19 antibody development, positioning AbCellera for future growth.

AbCellera reports Q3 results, advances innovative therapies and partnerships

AbCellera Biologics reported mixed financial results in Q3 2023 but demonstrated commitment to advancing innovative therapies and strategic partnerships.
Strengths lie in promising assets, financial stability, innovative molecule design, and progress on development candidates, while challenges include profitability concerns and operational complexities.
Opportunities for growth include expanding the product pipeline, exploring novel treatments through partnerships, and optimizing therapies for improved patient outcomes and market positioning.
Overall, AbCellera's performance reflects a balance of financial stability, innovation, and strategic focus, with future updates poised to drive investor interest and market impact.

AbCellera Biologics reports Q1 performance, highlights partnerships and growth

AbCellera Biologics showcased strong performance in Q1 2024, with a focus on advancing internal programs, strategic partnerships, and technological innovations.
Despite financial challenges, the company's strengths lie in its robust pipeline, strong financial position, and promising partnerships with industry leaders.
Navigating challenges in profitability and market competition, AbCellera has significant opportunities to drive growth through partnerships, technological advancements, and market expansion.

AbCellera Biologics reports Q2 revenue growth and strategic partnerships

AbCellera Biologics' Q2 2024 performance reflects a strong financial position, progress in key programs, and strategic partnerships driving future growth.
While facing challenges in profitability and research fee reductions, the company's focus on innovation and partnerships presents opportunities for market expansion.
Overall, AbCellera's emphasis on internal pipeline development and strategic collaborations positions them well for long-term success in the biologics industry.

AbCellera Biologics reports Q3 loss but poised for clinical advancements

AbCellera Biologics is navigating its transition to a clinical stage biotech with promising programs and a strong financial position.
While facing challenges in managing R&D expenses and achieving profitability, the company's strategic moves and preparedness for clinical trials bode well for future growth.
Opportunities lie in further investments in development, advancing novel therapies, and leveraging its financial strength to capitalize on emerging opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass. & VANCOUVER, British Columbia--(BUSINESS WIRE)--EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced a collaboration agreement for the discovery and development of therapeutic antibodies. The collaboration will leverage AbCellera's AI-powered antibody discovery technology to search and

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

HOUSTON & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer

Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of the earnings conference call will be available through a link that will be posted on AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call. A

AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Appoints Neil Berkley as Chief Business Officer

AbCellera Appoints Neil Berkley as Chief Business Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #antibodies--AbCellera Continues Expansion & Strengthens Future Pandemic Preparedness with GMP Manufacturing Facility for Therapeutic Antibodies in Canada

AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors (the “Buyers”), pursuant to which the Buyers purchased an aggregate 11,900,000 common share

AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares

I recommended AbCellera on March 8, 2021, and so far the stock has gone pretty much nowhere. However, I am as bullish as ever. Immediate catalysts are lacking, but that does not preclude you from accumulating this stock at a reasonable valuation before the fireworks start.

AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential Payoff

The stock price of AbCellera (Nasdaq: ABCL) increased by over 7% during intraday trading this morning. This is why it happened.

AbCellera (ABCL) Stock: Over 7% Increase Explanation

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q1 2021 Business Results

CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results

AbCellera stock tumbled Friday, despite in-line royalties for its Lilly-partnered Covid drug. Here's why the stock toppled.

Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug

AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript

AbCellera Reports Q1 2021 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

VANCOUVER, British Columbia & INNSBRUCK, Austria--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

Eli Lilly

AbCellera Biologics Inc (NASDAQ: ABCL) has announced that a second antibody from its collaboration with Eli Lilly and Co (NYSE: LLY), LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other monoclonal antibodies.

AbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human Trials

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

VANCOUVER, Canada--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals.

AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021

AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021

VANCOUVER, British Columbia & SAN DIEGO--(BUSINESS WIRE)---- $ABCL--AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present Virtually at Upcoming Investor Conferences

AbCellera to Present Virtually at Upcoming Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Published data show high potency of bamlanivimab against SARS-CoV-2 and support its clinical effectiveness to treat and prevent COVID-19.

Published Peer-Reviewed Data Demonstrate Bamlanivimab's High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19

Gilead Sciences

AbCellera Biologics Inc (NASDAQ: ABCL) has announced agreements to expand its collaboration with Gilead Sciences Inc (NASDAQ: GILD), including a multi-year, multi-target antibody discovery collaboration. Under the agreements' financial terms, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties.

AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) has increased by over 10% pre-market. This is why it happened.

ABCL Stock Price Increased Over 10% Pre-Market: Why It Happened

AbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript

News for AbCellera Biologics Stock (ABCL)